Historical Valuation
Bio Rad Laboratories Inc (BIO) is now in the Fair zone, suggesting that its current forward PE ratio of 29.16 is considered Fairly compared with the five-year average of 35.88. The fair price of Bio Rad Laboratories Inc (BIO) is between 263.34 to 461.96 according to relative valuation methord.
Relative Value
Fair Zone
263.34-461.96
Current Price：319.08
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Bio Rad Laboratories Inc (BIO) has a current Price-to-Book (P/B) ratio of 1.22. Compared to its 3-year average P/B ratio of 1.18 , the current P/B ratio is approximately 3.18% higher. Relative to its 5-year average P/B ratio of 1.35, the current P/B ratio is about -9.56% higher. Bio Rad Laboratories Inc (BIO) has a Forward Free Cash Flow (FCF) yield of approximately 4.08%. Compared to its 3-year average FCF yield of 2.65%, the current FCF yield is approximately 54.00% lower. Relative to its 5-year average FCF yield of 2.63% , the current FCF yield is about 55.28% lower.
P/B
Median3y
1.18
Median5y
1.35
FCF Yield
Median3y
2.65
Median5y
2.63
Competitors Valuation Multiple
AI Analysis for BIO
The average P/S ratio for BIO competitors is 2.69, providing a benchmark for relative valuation. Bio Rad Laboratories Inc Corp (BIO.N) exhibits a P/S ratio of 3.14, which is 16.42% above the industry average. Given its robust revenue growth of 0.50%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for BIO
1Y
3Y
5Y
Market capitalization of BIO increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of BIO in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is BIO currently overvalued or undervalued?
Bio Rad Laboratories Inc (BIO) is now in the Fair zone, suggesting that its current forward PE ratio of 29.16 is considered Fairly compared with the five-year average of 35.88. The fair price of Bio Rad Laboratories Inc (BIO) is between 263.34 to 461.96 according to relative valuation methord.
What is Bio Rad Laboratories Inc (BIO) fair value?
BIO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Bio Rad Laboratories Inc (BIO) is between 263.34 to 461.96 according to relative valuation methord.
How does BIO's valuation metrics compare to the industry average?
The average P/S ratio for BIO's competitors is 2.69, providing a benchmark for relative valuation. Bio Rad Laboratories Inc Corp (BIO) exhibits a P/S ratio of 3.14, which is 16.42% above the industry average. Given its robust revenue growth of 0.50%, this premium appears unsustainable.
What is the current P/B ratio for Bio Rad Laboratories Inc (BIO) as of Jan 09 2026?
As of Jan 09 2026, Bio Rad Laboratories Inc (BIO) has a P/B ratio of 1.22. This indicates that the market values BIO at 1.22 times its book value.
What is the current FCF Yield for Bio Rad Laboratories Inc (BIO) as of Jan 09 2026?
As of Jan 09 2026, Bio Rad Laboratories Inc (BIO) has a FCF Yield of 4.08%. This means that for every dollar of Bio Rad Laboratories Inc’s market capitalization, the company generates 4.08 cents in free cash flow.
What is the current Forward P/E ratio for Bio Rad Laboratories Inc (BIO) as of Jan 09 2026?
As of Jan 09 2026, Bio Rad Laboratories Inc (BIO) has a Forward P/E ratio of 29.16. This means the market is willing to pay $29.16 for every dollar of Bio Rad Laboratories Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Bio Rad Laboratories Inc (BIO) as of Jan 09 2026?
As of Jan 09 2026, Bio Rad Laboratories Inc (BIO) has a Forward P/S ratio of 3.14. This means the market is valuing BIO at $3.14 for every dollar of expected revenue over the next 12 months.